Smith & Nephew, Inc., a leading global medical technology company, is headquartered in the United States, with significant operations across Europe, Asia, and the Americas. Founded in 1856, the company has established itself in the orthopaedics, wound management, and sports medicine sectors, consistently innovating to improve patient outcomes. Renowned for its advanced surgical devices and wound care products, Smith & Nephew offers unique solutions such as the PICO™ single-use negative pressure wound therapy system and the JOURNEY™ knee system. These products are designed to enhance recovery and reduce complications, setting the company apart in a competitive market. With a strong market position, Smith & Nephew has achieved numerous accolades for its commitment to quality and innovation, making it a trusted name in the healthcare industry.
How does Smith & Nephew, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Smith & Nephew, Inc.'s score of 67 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Smith & Nephew, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Smith & Nephew plc, which may influence its climate commitments and emissions reporting. As of now, there are no documented reduction targets or climate pledges from Smith & Nephew, Inc. However, emissions data and performance metrics may be cascaded from its parent company, Smith & Nephew plc, which is responsible for reporting under the CDP framework. This relationship suggests that any climate initiatives or targets may align with those set by the parent organisation. In the absence of specific emissions figures, it is important to note that Smith & Nephew, Inc. is part of an industry increasingly focused on sustainability and reducing carbon footprints. The company may adopt similar strategies and commitments as its parent company in the future, reflecting a broader trend within the medical technology sector towards enhanced environmental responsibility.
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 10,123,000 | 00,000,000 | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 67,559,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 |
Smith & Nephew, Inc.'s Scope 3 emissions, which decreased by 48% last year and decreased by approximately 59% since 2021, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 73% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Smith & Nephew, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.